Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Aspirin Lysinate

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Dl-lysine acetylsalicylate, 62952-06-1, Aspegic, Egicalm, Aspirisine, Aspidol
    Molecular Formula
    C15H22N2O6
    Molecular Weight
    326.34  g/mol
    InChI Key
    JJBCTCGUOQYZHK-UHFFFAOYSA-N
    FDA UNII
    2JJ274J145
    Aspirin DL-Lysine is the lysine salt form of acetylsalicylic acid, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic and anti-inflammatory activities. Like other NSAIDs, aspirin DL-lysine inhibits the activity of cyclooxygenase I and II, resulting in decreased formation of prostaglandins (PGs) and thromboxanes precursors. This leads to decreased PG synthesis by PG synthase. This agent also causes a decrease in the formation of thromboxane A2 synthesis by thromboxane synthase, thereby inhibiting platelet aggregation.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-acetyloxybenzoic acid;2,6-diaminohexanoic acid
    2.1.2 InChI
    InChI=1S/C9H8O4.C6H14N2O2/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;7-4-2-1-3-5(8)6(9)10/h2-5H,1H3,(H,11,12);5H,1-4,7-8H2,(H,9,10)
    2.1.3 InChI Key
    JJBCTCGUOQYZHK-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(=O)OC1=CC=CC=C1C(=O)O.C(CCN)CC(C(=O)O)N
    2.2 Other Identifiers
    2.2.1 UNII
    2JJ274J145
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Acetylsalicylic Acid Lysinate

    2. Aspegic

    3. Aspirin Lysinate

    4. Aspirin Lysine

    5. Aspiryl-polylysine

    6. Aspisol

    7. Asprin Dl-lysine

    8. Flectadol

    9. L-lysine, 2-(acetyloxy)benzoate (1:1)

    10. Lysine Acetylsalicylate

    11. Lysine-acetylsalicylic Acid

    12. Lysine-aspirin

    13. Solusprin

    14. Solusprin, Monosalicylate, (dl-lys)-isomer

    15. Solusprin, Monosalicylate, (l-lys)-isomer

    16. Venopirin

    2.3.2 Depositor-Supplied Synonyms

    1. Dl-lysine Acetylsalicylate

    2. 62952-06-1

    3. Aspegic

    4. Egicalm

    5. Aspirisine

    6. Aspidol

    7. Solpirin

    8. Venopirin

    9. Vetalgine

    10. Dl-lysine-acetylsalicylate

    11. Flectadol

    12. Laspal

    13. L-lysine Acetylsalicylate

    14. Lysine Acetylsalicylic Acid

    15. Asl

    16. Lysine Acetylsalicylate,(s)

    17. Schembl25877

    18. 2-acetoxybenzoic Acid (1:1)

    19. Lysine Aspirin [mart.]

    20. Chembl1697753

    21. Dtxsid50886518

    22. Bcp12010

    23. Lysine Acetylsalicylate [mi]

    24. Akos025402349

    25. 2,6-diaminohexanoic Acid Compound With

    26. Ac-8243

    27. Dl-lysine Acetylsalicylate, Aldrichcpr

    28. Acetylsalicylate Lysine [who-dd]

    29. Ft-0670894

    30. Dl-lysine Acetylsalicylate [ep Monograph]

    31. 952l061

    32. Q15041214

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 326.34 g/mol
    Molecular Formula C15H22N2O6
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count8
    Exact Mass326.14778643 g/mol
    Monoisotopic Mass326.14778643 g/mol
    Topological Polar Surface Area153 Ų
    Heavy Atom Count23
    Formal Charge0
    Complexity318
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Analgesics

    Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)

    Anti-Inflammatory Agents, Non-Steroidal

    Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

    Cyclooxygenase Inhibitors

    Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)

    Platelet Aggregation Inhibitors

    Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)